[Medline] [Embase] [Central] [Previous Reviews] [Regulatory Agencies] [Trial Registries] [HTA] [Conferences]
Use Bokeh to create tabs for each category
Each tab has tables describing the strategy/terms for each individual source
PRISMA Flow Chart
Click the box to open a panel with the list of articles/records.
For exclusions, the record is tagged with a reason.
ARCHER 1009 2014
ClinicalTrials.gov: NCT01360554. A Study of Dacomitinib (PF-00299804) Vs. Erlotinib in The Treatment of Advanced Non-Small Cell Lung Cancer (ARCHER 1009).
PubMed: 25439691. Ramalingam SS, Janne PA, Mok T, O'Byrne K, Boyer MJ, VonPawel J, et al. Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): A randomised, double-blind, phase 3 trial. The Lancet Oncology. 2014;15(12):1369-78.
ASCO: 8018. Ramalingam SS, Janne PA, Mok T, O'Byrne K, Boyer MJ, Zhang H, et al. Randomized, double-blinded study of dacomitinib, an irreversible pan-human epidermal growth factor receptor (HER) inhibitor, versus erlotinib for second-line/third-line therapy of locally advanced/metastatic non-small cell lung cancer (ARCHER 1009). Journal of Clinical Oncology. 2014;32(15):8018.
ESMO: 1243P. Mok T, O’Byrne K, Ramalingam S, Janne P, Boyer M, Ahn J, et al. Dacomitinib versus Erlotinib in second/third line NSCLC: outcome for asian patients from the ARCHER 1009 Global Phase 3 trial. Annals of Oncology. 2014;25(4): iv426–iv70.